Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Sci Rep ; 8(1): 314, 2018 01 10.
Article in English | MEDLINE | ID: mdl-29321514

ABSTRACT

Pneumococcal flavin reductase (FlaR) is known to be cell-wall associated and possess age dependent antigenicity in children. This study aimed at characterizing FlaR and elucidating its involvement in pneumococcal physiology and virulence. Bioinformatic analysis of FlaR sequence identified three-conserved cysteine residues, suggesting a transition metal-binding capacity. Recombinant FlaR (rFlaR) bound Fe2+ and exhibited FAD-dependent NADP-reductase activity, which increased in the presence of cysteine or excess Fe2+ and inhibited by divalent-chelating agents. flaR mutant was highly susceptible to H2O2 compared to its wild type (WT) and complemented strains, suggesting a role for FlaR in pneumococcal oxidative stress resistance. Additionally, flaR mutant demonstrated significantly decreased mice mortality following intraperitoneal infection. Interestingly, lack of FlaR did not affect the extent of phagocytosis by primary mouse peritoneal macrophages but reduced adhesion to A549 cells compared to the WT and complemented strains. Noteworthy are the findings that immunization with rFlaR elicited protection in mice against intraperitoneal lethal challenge and anti-FlaR antisera neutralized bacterial virulence. Taken together, FlaR's roles in pneumococcal physiology and virulence, combined with its lack of significant homology to human proteins, point towards rFlaR as a vaccine candidate.


Subject(s)
Bacterial Adhesion , Bacterial Proteins/genetics , FMN Reductase/genetics , Oxidative Stress , Streptococcus pneumoniae/pathogenicity , Animals , Bacterial Proteins/metabolism , Cell Line, Tumor , Cells, Cultured , FMN Reductase/metabolism , Female , Humans , Macrophages, Peritoneal/microbiology , Mice , Mice, Inbred BALB C , Mice, Inbred CBA , Mutation , Phagocytosis , Streptococcus pneumoniae/enzymology , Streptococcus pneumoniae/genetics , Virulence/genetics
2.
PLoS One ; 11(3): e0150320, 2016.
Article in English | MEDLINE | ID: mdl-26990554

ABSTRACT

In Streptococcus pneumonia, phosphoenolpyruvate protein phosphotransferase (PtsA) is an intracellular protein of the monosaccharide phosphotransferase systems. Biochemical and immunostaining methods were applied to show that PtsA also localizes to the bacterial cell-wall. Thus, it was suspected that PtsA has functions other than its main cytoplasmic enzymatic role. Indeed, recombinant PtsA and anti-rPtsA antiserum were shown to inhibit adhesion of S. pneumoniae to cultured human lung adenocarcinoma A549 cells. Screening of a combinatorial peptide library expressed in a filamentous phage with rPtsA identified epitopes that were capable of inhibiting S. pneumoniae adhesion to A549 cells. The insert peptides in the phages were sequenced, and homologous sequences were found in human BMPER, multimerin1, protocadherin19, integrinß4, epsin1 and collagen type VIIα1 proteins, all of which can be found in A549 cells except the latter. Six peptides, synthesized according to the homologous sequences in the human proteins, specifically bound rPtsA in the micromolar range and significantly inhibited pneumococcal adhesion in vitro to lung- and tracheal-derived cell lines. In addition, the tested peptides inhibited lung colonization after intranasal inoculation of mice with S. pneumoniae. Immunization with rPtsA protected the mice against a sublethal intranasal and a lethal intravenous pneumococcal challenge. In addition, mouse anti rPtsA antiserum reduced bacterial virulence in the intravenous inoculation mouse model. These findings showed that the surface-localized PtsA functions as an adhesin, PtsA binding peptides derived from its putative target molecules can be considered for future development of therapeutics, and rPtsA should be regarded as a candidate for vaccine development.


Subject(s)
Cell Wall/enzymology , Phosphoenolpyruvate Sugar Phosphotransferase System/metabolism , Phosphotransferases (Nitrogenous Group Acceptor)/metabolism , Pneumococcal Vaccines/immunology , Streptococcus pneumoniae/enzymology , Adhesins, Bacterial/physiology , Cell Line, Tumor , Child, Preschool , Flow Cytometry , Humans , Streptococcus pneumoniae/immunology
3.
PLoS One ; 8(4): e61128, 2013.
Article in English | MEDLINE | ID: mdl-23577197

ABSTRACT

The initial event in disease caused by S. pneumoniae is adhesion of the bacterium to respiratory epithelial cells, mediated by surface expressed molecules including cell-wall proteins. NADH oxidase (NOX), which reduces free oxygen to water in the cytoplasm, was identified in a non-lectin enriched pneumococcal cell-wall fraction. Recombinant NOX (rNOX) was screened with sera obtained longitudinally from children and demonstrated age-dependent immunogenicity. NOX ablation in S. pneumoniae significantly reduced bacterial adhesion to A549 epithelial cells in vitro and their virulence in the intranasal or intraperitoneal challenge models in mice, compared to the parental strain. Supplementation of Δnox WU2 with the nox gene restored its virulence. Saturation of A549 target cells with rNOX or neutralization of cell-wall residing NOX using anti-rNOX antiserum decreased adhesion to A549 cells. rNOX-binding phages inhibited bacterial adhesion. Moreover, peptides derived from the human proteins contactin 4, chondroitin 4 sulfotraferase and laminin5, homologous to the insert peptides in the neutralizing phages, inhibited bacterial adhesion to the A549 cells. Furthermore, rNOX immunization of mice elicited a protective immune response to intranasal or intraperitoneal S. pneumoniae challenge, whereas pneumococcal virulence was neutralized by anti-rNOX antiserum prior to intraperitoneal challenge. Our results suggest that in addition to its enzymatic activity, NOX contributes to S. pneumoniae virulence as a putative adhesin and thus peptides derived from its target molecules may be considered for the treatment of pneumococcal infections. Finally, rNOX elicited a protective immune response in both aerobic and anaerobic environments, which renders NOX a candidate for future pneumococcal vaccine.


Subject(s)
Adhesins, Bacterial/metabolism , Immunity , Multienzyme Complexes/metabolism , NADH, NADPH Oxidoreductases/metabolism , Streptococcus pneumoniae/enzymology , Adhesins, Bacterial/genetics , Adhesins, Bacterial/immunology , Aerobiosis , Aging/immunology , Anaerobiosis , Animals , Bacterial Adhesion/drug effects , Bacterial Vaccines/genetics , Bacterial Vaccines/immunology , Bacterial Vaccines/metabolism , Cell Line , Child, Preschool , Female , Gene Deletion , Gene Expression Regulation, Bacterial/drug effects , Humans , Infant , Mice , Multienzyme Complexes/deficiency , Multienzyme Complexes/genetics , Multienzyme Complexes/immunology , NADH, NADPH Oxidoreductases/deficiency , NADH, NADPH Oxidoreductases/genetics , NADH, NADPH Oxidoreductases/immunology , Peptides/pharmacology , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/genetics , Streptococcus pneumoniae/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...